Adar Poonawalla receives Covishield shot, wishes PM Modi success

Serum Institute of India (SII) CEO Adar Poonawalla on Saturday wished Prime Minister Narendra Modi success in launching the vaccination rollout in the country

Adar Poonawalla, CEO, Serum Institute
Adar Poonawalla, CEO, Serum Institute
ANI General News
2 min read Last Updated : Jan 16 2021 | 2:44 PM IST

Serum Institute of India (SII) CEO Adar Poonawalla on Saturday wished Prime Minister Narendra Modi success in launching the vaccination rollout in the country.

"I wish India and Sri Narendra Modi ji great success in launching the world's largest COVID vaccination roll-out. It brings me great pride that #COVISHIELD is part of this historic effort and to endorse its safety and efficacy, I join our health workers in taking the vaccine myself," Poonawalla tweeted while posting a video in which he was seen receiving the vaccine shot.

The drugs regulatory body of India has currently approved two vaccines. Pune-based Serum Institute of India has developed the Covishield vaccine developed by AstraZeneca and Oxford University while the Covaxin has been developed by Hyderabad's Bharat Biotech in collaboration with the Indian Medical Council of research (ICMR) and National Institute of Virology.

Earlier in the day, the Prime Minister launched India's vaccination drive against the novel coronavirus via video conferencing.

Billed as the world's largest vaccination program, covering the entire length and breadth of the country, the drive aims to first inoculate millions of its healthcare and frontline workers and reach an estimated 3 crore people by the end of its first phase.

A total of 3006 session sites across all states and union territories will be virtually connected during the launch. Around 100 beneficiaries will be vaccinated at each session site on the inaugural day, the union health ministry had said.

In the first phase government and private sector health care workers, including Integrated Child Development Services (ICDS) workers, will receive the vaccine.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusSerum Institute of IndiaCoronavirus Vaccine

First Published: Jan 16 2021 | 2:41 PM IST

Next Story